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Abstract   
Obesity associates with the endoplasmic reticulum (ER) stress-induced endothelial 
dysfunction. Pregnant women with pre-pregnancy maternal obesity (PGMO) may transfer 
this potential risk to their offspring; however, whether ER stress occurs and associates with 
foetoplacental endothelial dysfunction in PGMO is unknown. We studied the L-arginine 
transport and nitric oxide (NO) synthesis in human umbilical vein endothelial cells 
(HUVECs) from women with PGMO or with a normal pre-pregnancy weight. We analysed 
the expression and activation of the ER stress sensors protein kinase RNA-like endoplasmic 
reticulum kinase (PERK), inositol-requiring enzyme 1α (IRE1α), and activating 
transcription factor 6 (ATF6). PGMO associated with lower endothelial NO synthase 
activity due to increased Thr
495
-inhibitor and decreased Ser
1177
-stimulator phosphorylation. 
However, higher expression and activity of the human cationic amino acid transporter 1 
was found. PGMO caused activation of PERK and its downstream targets eukaryotic 
initiation factor 2 (eIF2α), C/EBP homologous protein 10 (CHOP), and tribbles-like protein 
3 (TRB3). Increased IRE1α protein abundance (but not its phosphorylation or X-box 
binding protein 1-mRNA splicing) and increased c-Jun N-terminal kinase 1 
phosphorylation was seen in PGMO. A preferential nuclear location of the activating 
transcription factor 6 (ATF6) was found in HUVECs from PGMO. All the changes seen in 
PGMO were blocked by TUDCA but unaltered by tunicamycin. Thus, PGMO may 
determine a state of ER stress via upregulation of the PERK–eIF2–CHOP–TRB3 axis 
signalling in HUVECs. This phenomenon results in foetoplacental vascular endothelial 
dysfunction at birth.   
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Abbreviations 
 
PGMO Pre-gestational maternal obesity 
PGMN Pre-gestational maternal normal weight  
HUVECs Human umbilical vein endothelial cells 
NO  Nitric oxide 
NOS  Nitric oxide synthase 
eNOS  Endothelial nitric oxide synthase 
Akt  Protein kinase B/Akt 
ER  Endoplasmic reticulum 
UPR  Unfolded protein response 
PERK  RNA-like endoplasmic reticulum kinase 
IRE1α  Inositol-requiring enzyme 1-alpha 
ATF6  Activating transcription factor 6 
hCAT-1 Human cationic amino transporter 1 
JNK1  c-Jun N-terminal kinase 1 
TRB3  Tribbles-like protein 3 
CHOP  C/EBP homologous protein 10 
BIP  Binding immunoglobulin protein 
NBCS  Newborn calf serum 
FCS  Foetal calf serum 
L-NAME N
G
-Nitro-L-arginine methyl ester 
DAF-FM 4-Amino-5-methylamino-2',7'-difluorofluorescein 
BMI  Body mass index 
TUDCA Tauroursodeoxycholic acid 
OGTT  Oral glucose tolerance test 
PBS  Phosphate buffer solution 
PCM  Primary culture medium 
SDS  Sodium dodecylsulphate 
BSA  Bovine serum albumin 
HSP90  Heat-shock protein 90 
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1. Introduction 
Obesity is considered an epidemic in developing and developed countries [1]. Pre-
gestational maternal obesity (PGMO) characterizes by women with a body mass index 
(BMI) ≥30 kg/m2 [1] and is a risk factor for infant and adolescent obesity [2]. PGMO is 
also associated with the development of metabolic syndrome and increased risk of 
cardiovascular disease in adulthood [3–5]. Even when the placental transfer of harmful 
factors from obese mothers to children is known [6–8], the mechanism(s) involved in the 
maternal-to-foetal transfer of risk for PGMO-associated diseases is not fully understood 
[7,9]. Endothelial dysfunction is a key phenomenon in cardiovascular disease [10]. 
Maternal obesity has been associated with altered foetoplacental [11] and endothelial 
dysfunction seen as a reduced response to endothelium-dependent vasodilators [12] and 
endothelial nitric oxide synthase (eNOS) activation and nitric oxide (NO) generation, likely 
due to reduced protein kinase B/Akt (Akt) activity [9], in human umbilical vein endothelial 
cells (HUVECs) [12]. However, nothing is reported regarding PGMO effect on the 
foetoplacental endothelial function.  
Obese subjects show over-activation of the unfolded protein response (UPR) in the 
antecubital vein endothelial cells suggesting a condition of endoplasmic reticulum (ER) 
stress [13]. ER stress is induced by stimuli such as accumulation of unfolded proteins, fatty 
acids, cytokines, redox state dysregulation, or increased intracellular Ca
2+
 levels [14]. ER 
stress also triggers a UPR following activation of three canonical ER stress sensors, i.e., 
protein kinase RNA-like endoplasmic reticulum kinase (PERK), inositol-requiring enzyme 
1α (IRE1α), and activating transcription factor 6 (ATF6) [14]. These ER stress sensors 
initiate differential downstream cell signalling sharing common pathways that lead to 
prosurvival or proapoptotic responses [15]. Antecubital vein endothelial cells from non-
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pregnant obese women show higher IRE1 expression, PERK phosphorylation, and ATF6 
nuclear localization [13]. ER stress also reduced eNOS activation and NO generation in 
HUVECs [16] and associated with endothelial dysfunction and reduced insulin response in 
mouse mesenteric [17] and coronary [18] arteries. Also, skeletal muscle from pregnant 
women with PGMO presents with ER stress [19]. However, whether PGMO causes ER 
stress sensors activation in the foetoplacental vascular endothelium is unknown. We 
hypothesize that ER stress is likely in the foetoplacental endothelium from PGMO 
pregnancies leading to endothelial dysfunction in this vascular bed. We evaluated the 
activation of UPR proteins and the effect of ER stress on the L-arginine transport and NO 
synthesis in HUVECs from PGMO.  
 
2. Material and methods 
2.1 Antibodies and materials 
Primary monoclonal mouse anti-hCAT-1 and anti-ß-actin were from Sigma Aldrich 
(St Louis, MO, USA). Primary polyclonal rabbit anti-total eIF2α and anti-eIF2α 
phosphorylated at Ser
51
, and rabbit anti-total Akt and anti-Akt phosphorylated at Ser
473
 
were from Cell Signaling Technology, Inc. (Danvers, MA, USA). Primary monoclonal 
mouse anti-eNOS phosphorylated at serine
1177
 and anti-eNOS phosphorylated at 
threonine
495
 were from BD Transduction Laboratories (Franklin Lakes, NJ, USA). Primary 
polyclonal rabbit anti-ATF6, anti-total IRE1α, anti-IRE1α phosphorylated at Ser724, anti-
total JNK1 and anti-JNK1 phosphorylated at Thr
183
/Tyr
185
 were from Abcam (Cambridge, 
UK). Polyclonal rabbit anti-TRB3 was from Merck Millipore (Billirica, MA, USA). 
Polyclonal rabbit anti-total PERK, anti-PERK phosphorylated at Thr
981
, anti-total eNOS, 
anti-CHOP, and secondary horseradish peroxidase-conjugated goat anti-rabbit or anti-
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mouse antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). For 
isolation of HUVECs from umbilical cords, Collagenase Type II from Clostridium 
histolyticum (Boehringer, Mannheim, FRG) was used. Medium M199, newborn (NBCS) 
and fetal calf (FCS) sera, L-glutamine, and penicillin-streptomycin were from Gibco Life 
Technologies (Carlsbad, CA, USA). L-[
3
H]Arginine and D-[
3
H]mannitol were from NEN 
(Dreieich, FRG). N
G
-Nitro-L-arginine methyl ester (L-NAME) was from Sigma Aldrich. 
Immobilon-P polyvinylidene difluoride membranes were from BioRad Laboratories 
(Hertfordshire, UK). Qiagen RNAeasy kit was from Qiagen (Crawley, UK) and brilliant 
SYBR green qPCR Master Mix from Stratagene (La Jolla, CA, USA). The fluorescent dye 
4-amino-5-methylamino-2',7'-difluorofluorescein (DAF-FM), tauroursodeoxycholic acid 
(TUDCA), and tunicamycin were from Merck Millipore (Billirica, MA, USA). 
 
2.2 Study groups 
Pregnant women with pre-pregnancy normal weight (n = 20) (hereafter referred as 
‘PGMN’, BMI 18.5–24.9 kg/m2) or with pre-pregnancy obesity (n = 22) (hereafter referred 
as ‘PGMO’, BMI 30 kg/m2) [1,20] were included in this study. PGMN group was selected 
based on the following exclusion criteria: pre-pregnancy maternal overweight (BMI 25–
29.9 kg/m
2
) or obesity, previous multiple pregnancies, foetal malformations, hypertensive 
syndrome, preeclampsia, intrauterine growth restriction, pre-pregnancy or gestational 
diabetes mellitus. The exclusion criteria for PGMO were PGMN or overweight, and the 
listed exclusion criteria for PGMO. Deliveries by caesarean section were excluded from the 
study groups. Therefore, all deliveries were full-term normal vaginal deliveries. Pregnant 
women included in this study did not smoke or consume drugs or alcohol and had no 
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intrauterine infection or any other medical or obstetrical complications. The ethnicity of 
patients included in this study was Hispanic. The investigation conforms to the principles 
outlined in the Declaration of Helsinki and counts with Ethics Committee approval from 
the Faculty of Medicine of the Pontificia Universidad Católica de Chile. Patient written, 
informed consents were obtained 12-24 h before delivery.  
The weight of the women before confirming their pregnancy was the one they 
reported from their own measurements. All pregnant women were evaluated for weight and 
height, and BMI was recorded at the first interview with the treating obstetrician (i.e., 5–12 
weeks of gestation, 1
st
 trimester of pregnancy), then at the 2
nd
 (14–28 weeks of gestation) 
and 3
rd
 (28–40 weeks of gestation) trimesters of pregnancy, and at delivery (37.1-41 weeks 
of gestation). Pregnant women with a normal glycaemia at the first trimester of pregnancy 
were also evaluated by an oral glucose tolerance test (OGTT) with a unique glucose load 
(75 g fasting) at 24-28 weeks of gestation to discard gestational diabetes mellitus 
(according to the Perinatal Guide 2015 from the Health Ministry of Chile) [21]. A basal 
glycaemia <5.55 mmol/L (<100 mg/dL) after 8-9 h from last feeding and <7.9 mmol/L 
(<140 mg/dL) at 2 h after glucose load was considered as normal [21]. 
 
2.3 Human placenta and umbilical cords  
Placentas were collected at delivery on ice and transferred to the laboratory until use 
15-30 min later. Middle sections of umbilical cords (100-120 mm length) were dissected 
into 200 mL phosphate-buffered saline (PBS) solution (mmol/L: 130 NaCl, 2.7 KCl, 0.8 
Na2HPO4, 1.4 KH2PO4, pH 7.4, 4ºC) and kept in this solution until use 6-12 h later for 
isolation of endothelial cells as described [22]. 
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2.4 Cell culture 
HUVECs were isolated by collagenase digestion (0.25 mg/mL collagenase) from 
umbilical cords obtained at birth from PGMN or PGMO pregnancies and cultured (37°C, 
5% CO2) in 1% gelatin-coated Petri dishes (100 mm diameter) up to passage 3 in primary 
culture medium (PCM; M199 containing 5 mmol/L D-glucose, 10% NBCS, 10% FCS, 3.2 
mmol/L L-glutamine, and 100 U/mL penicillin-streptomycin) [12,22]. Twelve hours prior 
experiments the incubation medium was changed to M199 medium containing 1% NBCS 
and 1% FCS. Cells isolation and culture was done in parallel placentas, i.e., one PGMO 
with its corresponding PGMN, taken from the total number of samples for each condition 
(i.e., n = 20 from pregnant women with PGMN and n = 22 from pregnant women with 
PGMO). Experiments were performed in the absence or presence of tunicamycin (5 
µmol/L, 8 h, inducer of ER stress) [23], TUDC  (100 µmol/L, 8 h, reducer of ER stress), 
tunicamycin + TUDCA (8 h) [24], or L-NA E (100 µmol/L, 20 min, NOS inhibitor) [25]. 
 
2.5 L-Arginine uptake and transport kinetics 
 L-Arginine uptake for different concentrations of this amino acid (0-1000 μmol/L, 
3 μCi/mL L-[3H]arginine, 1 min incubation, 37°C) (hereafter referred as ‘overall uptake’) 
was measured in cells from PGMN (n = 12 different women) and PGMO (n = 12 different 
women) incubated in Krebs solution (mmol/L: 131 NaCl, 5.6 KCl, 25 NaHCO3, 1 
NaH2PO4, 20 Hepes, 2.5 CaCl2, 1 MgCl2, pH 7.4, 37ºC), as described [22,26]. Overall 
uptake of L-arginine was defined as the result of the sum of a saturable component plus a 
nonsaturable, linear component of uptake in the range of L-arginine concentrations used in 
this study (hereafter referred as a KD value defined by m•[Arg], where m corresponds to 
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slopes of linear phases of uptake at a given L-arginine concentration [Arg]) [22,26]. Cell 
monolayers were rinsed with ice-cold Krebs to terminate tracer uptake.  
The initial rate of uptake (i.e., linear uptake up to 1 min) was derived from the slope 
of the linear phases of L-arginine uptakes. Values for uptake were adjusted to the one phase 
exponential association equation
 
considering the least squares fit: 
 
 
 
where vi is initial velocity, Vm is the highest velocity reached at a given time (t) and L-
arginine concentration, and e and k are constants.  
The overall uptake vales at initial rates of the whole range of L-arginine 
concentrations used in this study (i.e., hereafter referred as overall L-arginine transport) 
was adjusted to the Michaelis-Menten hyperbola plus a nonsaturable, linear component 
(KD) as described [22,26]. The saturable transport of L-arginine was derived by subtracting 
the m•[Arg] components from overall transport, and the transport kinetic parameters 
maximal velocity (Vmax) and apparent Michaelis-Menten constant (Km) of transport were 
calculated [22,26]. Each transport assay was run in duplicate with transport activity 
expressed as pmol/µg protein/minute. Radioactivity in 0.5N KCl cell digests was 
determined by liquid scintillation counting, and uptake was corrected for D-[
3
H]mannitol 
disintegrations per minute (d.p.m.) in the extracellular space [22].  
 
2.6 Western blotting 
Total protein was obtained from confluent cells from PGMN (n = 9 different 
women) and PGMO (n = 9 different women), washed twice with ice-cold PBS and 
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harvested in 100 μL of lysis buffer composed by 63.7 mmol/L Tris/HCl (pH 6.8), 10% 
glycerol, 2% sodium dodecyl sulphate (SDS), 1 mmol/L sodium orthovanadate, 50 mg/mL 
leupeptin, and 5% 2-mercaptoethanol, as described [22]. Cells were sonicated (6 cycles, 5 s, 
100 Watts, 4ºC), and total protein was separated by centrifugation (14000 g, 15 min, 4°C). 
Proteins (70 µg) were separated by SDS-polyacrylamide gel (10%) electrophoresis and 
transferred onto Immobilon-P polyvinylidene difluoride membranes. The proteins were 
then probed against hCAT-1 (1:1000 dilution, 12 h, 4ºC), total eNOS (1:1000 dilution, 3 h, 
room temperature), eNOS phosphorylated at serine
1177
 (PSer1177-eNOS, 1:1000 dilution, 
12 h, 4ºC), eNOS phosphorylated at threonine
495
 (PThr495-eNOS, 1:1000 dilution, 12 h, 
4ºC), total Akt (1:1000 dilution, 3 h, room temperature), Akt phosphorylated at serine
473
 
(PSer473Akt, 1:1000 dilution, 3 h, room temperature), total PERK (1:500 dilution, 12 h, 
4°C), PERK phosphorylated at threonine
981 
(PThr981PERK, 1:500 dilution, 12 h, 4°C), 
total eIF2α (1:1000 dilution, 12 h, 4°C), eIF2α phosphorylated at serine51 (PSer51eIF2α, 
1:1000 dilution, 12 h, 4°C), CHOP (1:1000 dilution, 12 h, 4°C), TRB3 (1:1000 dilution, 12 
h, 4°C), total IRE1α (1:1000 dilution, 12 h, 4°C), IRE1α phosphorylated at serine724 
(PSer724IRE1α, 1:1000 dilution, 12 h, 4°C), total JNK1 (1:1000 dilution, 12 h, 4°C), JNK1 
phosphorylated at threonine
183
 and tyrosine
185 
(PThr183/Tyr185JNK1, 1:1000 dilution, 12 h, 
4°C), and ß-actin (1:5000, 1 h, room temperature, loading control). Membranes were rinsed 
in Tris buffer saline plus 0.5% Tween (TBS-T) and incubated (1 h) in TBS-T/0.5% fat-free 
milk containing secondary horseradish peroxidase-conjugated antibodies. Proteins were 
detected by enhanced chemiluminescence in a ChemiDoc-It 510 Imagen System (UVP, 
LCC Upland, CA, USA) at the linear phase of luminescence for each antibody for the target 
proteins analysed and quantified by densitometry [22].  
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2.7 Isolation of total RNA and reverse transcription 
Total RNA was isolated from PGMN (n = 8 different women) and PGMO (n = 8 
different women) using the Qiagen RNAeasy kit. RNA quality and integrity were insured 
by gel visualization and spectrophotometric analysis (OD260/280), quantified at 260 nm as 
described [22]. Aliquots (2 μg) of total RNA were reversed transcribed into cDNA. 
 
2.8 Quantitative PCR 
Experiments were performed using a StepOne Real-Time PCR system (Applied 
Biosystems, Foster City, CA, USA) in a reaction mix containing 0.5 μmol/L primers, and 
master mix provided in the brilliant SYBR green qPCR Master Mix as described [22]. Hot-
start DNA polymerase was activated (20 s, 95°C), and the PCR cycling profile included a 
95ºC denaturation (3 s), annealing (30 s) at 56°C (CHOP, TRB3, BIP, XBP1, and β-actin) 
and 54ºC (28S), and extension (30 s) at 72ºC. Product melting temperature values were 
79.3°C (CHOP), 83.7°C (TRB3), 73.8°C (BIP), 80.2°C (β-actin), and 80ºC (28S). Primers 
efficiency were 101.5% (CHOP), 91.3% (TRB3), 103.1% (BIP), 93.3% (β-actin), and 
109.3% (28S). The oligonucleotide primers used in this study were: CHOP sense: 5’-
AATGAACGGCTCAAGCAGGA-3’, CHOP anti-sense: 5’-
TGCAGATTCACCATTCGGTCA-3’, TRB3 sense: 5’-
ATTAGGCAGGGTCTGTCCTGTG-3’, TRB3 anti-sense: 5’-
AGTATGGACCTGGGATTGTGGA-3’, BIP sense 5’-CCACCAAGATGCTGACATTG-
3’, BIP anti-sense: 5’-AGGGCCTGCACTTCCATAGA-3’, XBP1 sense: 5’-
GGAGTTAAGACAGCGCTTGGGGA-3’ XBP1 anti-sense: 5’-
TGTTCTGGAGGGGTGACAACTGGG-3’, β-actin sense: 5’-
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GCCGGGACCTGACTGACTAC-3’, β-actin anti-sense: 5’- 
TTCTCCTTAATGTCACGCACGAT-3’, 28S sense: 5′-TTGAAAATCCGGGGGAGAG-
3′, 28S anti-sense: 5′-ACATTGTTCCAACATGCCAG-3′. Expected size products were 
CHOP 89 bp, TRB3 90 bp, BIP 100 bp, β-actin 100 bp, 28S 100 bp, XBP1 164 bp (spliced) 
and 138 bp (unspliced). The threshold cycle (Ct) value was defined as the PCR cycle 
number at which the fluorescent signal of the probes exceeded background and was used 
for calculating gene expression data with the 2
–ΔΔCt
 method [27]. The amplification of the 
control genes 28S and -actin was linear between 14–37.5 and 7–35 Ct, respectively. 
Equally, target genes TRB3, CHOP, and BIP amplification was linear within 5–33, 5–35, 
and 10–35 Ct, respectively. Experimental samples amplification was linear with 20–26, 26–
34, and 18–28 Ct for TRB3, CHOP, and BIP, respectively. Amplification of control genes 
28S and -actin was similar in the experimental groups PGMN and PGMO in the absence 
or presence of tunicamycin, TUDCA, or both molecules (not shown). For XBP1, the 
amplified cDNA was separated on a 1.5% agarose gel to differentiate the spliced and 
unspliced XBP1 cDNA as described [28].  
 
2.9 Intracellular NO determination 
Intracellular NO was determined using the fluorescent dye DAF-FM as described 
[22]. Confluent cells from PGMN (n = 8 different women) and PGMO (n = 8 different 
women) grown on 100 mm
2
 culture plate were incubated in the absence or presence of 
tunicamycin (5 µmol/L, 8 h) and TUDCA (100 µmol/L, 8 h), and then exposed (1 h, 37ºC) 
to 5 μmol/L DAF-FM in the absence or presence of 100 µmol/L L-NAME in Krebs buffer 
(37ºC, pH 7.4). The fraction of NOS-activity derived NO was estimated by the difference 
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between the fluorescence in the presence and absence of L-NAME. The fluorescence 
(λexc/λem : 485/538 nm) was determined in an Infinite M200PRO Tecan (Männedorf, 
Zürich, Switzerland). 
 
2.10. NOS activity 
The activity of NOS was assayed by quantification of the intracellular content of L-
citrulline by high performance liquid chromatography (h.p.l.c.) in HUVECs from PGMN (n 
= 3 different women) and PGMO (n = 3 different women) in the absence or presence of 100 
μmol/L L-NAME, as described [22]. 
 
2.11 Arginase activity 
Total urea production from L-arginine was measured as previously described in 
HUVECs [29]. In brief, total cell protein aliquotes (70 μg contained in 90 μL) obtained 
from cells from PGMN (n = 3 different women) and PGMO (n = 3 different women) 
incubated in the absence or presence of 20 μmol/L S-(2-boronoethyl)-L-cysteine (BEC, 
arginases inhibitor) [30], were preincubated (10 min, 55°C) with 100 mmol/L MnCl2 in 50 
mmol/L Tris-HCl (pH 7.5) and then mixed with L-arginine (50 mmol/L, 60 min, 37°C). 
The reaction was stopped by addition (400 μL) of an acid mix (H2SO4:H3PO4:H2O = 1:3:7 
v/v) and incubated (45 min, 100°C) with 9% -isonitrosopropiophenone (25 μL) for 
colorimetric determination of urea (absorbance at 540 nm) in a microplate reader (Thermo 
Labsystems, Waltham, MA, USA). Arginases activity was calculated from the urea 
formation in the absence of BEC minus the urea formation in the presence of this inhibitor 
[29,30]. Activity was expressed as pmol urea/μg protein/minute.  
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2.12  Confocal laser scanning microscopy 
HUVECs were grown on glass coverslips (6 x10
4
 cells per slide) (Sail Brand, 
Shanghai, China) in PCM to 100% confluence as described [12]. Cells were then cultured 
in medium M199 containing 1% FCS and 1% NBCS in the absence or presence of 
tunicamycin (5 µmol/L, 8 h), TUDCA (100 µmol/L, 8 h), or both molecules, then fixed in 
4% paraformaldehyde (5 min), rinsed (x3) with PBS, permeabilised, and blocked with 1% 
BSA-containing blocking solution (50 mmol/L NH4Cl, and 0.05% Triton X-100 in PBS (2 
h) [31]. ATF6 was immunolocalised by incubating the cells with primary monoclonal 
rabbit anti-ATF6 (1:30 dilution) (Spring Bioscience, Pleasanton, CA, USA) overnight at 
4°C in 1% BSA-blocking solution. The cells were then washed (x3) with PBS, followed by 
incubation (1 h, 22°C) with the secondary antibody Alexa Fluor 568 goat anti-rabbit IgG 
(H+L, exc/em: 578/603 nm, 1:500 dilution) (Life Technologies) in 1% BSA-blocking 
solution. Nuclei were counterstained with DAPI (5 μmol/L, Life Technologies) and 
mounted with Fluoromount G (Electron Microscopy Sciences, Washington, PA, USA). 
Images were acquired under an inverted Eclipse C2 confocal Nikon microscope using a 60x 
oil immersion objective lens (numerical aperture 1.4) and the confocal acquisition software 
NIS-Elements C (Nikon, Tokio, Japan). Each sample was examined through successive 0.3 
μm optical slices along the z axis to capture 15 slices per cell. Relative fluorescence was 
measured using ImageJ version 1.52b (Wayne Rasband NIH, USA) [32] and the ratio 
between the ATF6 fluorescence at the nuclear region and the perinuclear region of each cell 
was determined. Nuclear regions defined by DAPI fluorescence were also analysed for the 
optical slide number 7, i.e., 2.1 m from cell culture surface. ATF6 fluorescence at the 
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perinuclear region (pnA) was derived from the expression pnA = (1.9  nA) – nA, where nA 
is the nuclear region corresponding to DAPI fluorescence and 1.9 is the increase in the nA 
fixed for each cell analysed. 
 
2.14 Statistical analysis 
The sample size was estimated considering a power of 80% enough to detect 
differences between both groups (based on a two-sided alpha level of 0.05). Values for 
clinical parameters are given as mean ± S.D. (range). For in vitro assays the values are 
mean ± S.E.M., where n indicates the number of different biological samples for which 
each assay was replicated 2-3 times. Comparisons between two groups were performed by 
means of Student’s unpaired t-test or Mann-Whitney test for parametric or non-parametric 
data, respectively. The differences between more than two groups were performed by 
analysis of variance (one-way or two-way ANOVA). If ANOVA demonstrated a significant 
interaction between variables, post hoc analyses were performed by the Bonferroni 
multiple-comparison. The statistical software GraphPad Instat 3.0b and Graphpad Prism 
8.0a.91 (GraphPad Software Inc., San Diego, CA, USA) were used for data analysis. 
P<0.05 was considered statistically significant. 
 
3. Results 
3.1 Study groups 
Pregnancies were a singleton, and pregnant women showed with similar age and 
height, were normotensive, with similar OGTT and normal glycaemia at delivery (Table 1). 
The pre-pregnancy weight and BMI were higher in PGMO compared with PGMN. The 
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total gestational weight gain (tGWG) and rate of GWG (rGWG) for 2
nd
 to 3
rd
 trimester of 
pregnancy (
2nd-3rd
rGWG) were within the recommended values for pregnant women with a 
normal pre-pregnancy BMI (tGWG 11.5–16 kg, 2nd-3rdrGWG 0.42 kg per week) or pre-
pregnancy obesity (BMI 30 kg/m2) (tGWG 5–9 kg, 2nd-3rdrGWG 0.22 kg per week) 
according to the 2009 US Institute of Medicine (IOM) guidelines (IOM, 2009).  
The tGWG was higher (2.18  0.9 fold) in PGMN compared with PGMO (Table 1). 
Women from the PGMN group show an increase but from the PGMO group show a 
decrease in the GWG change (GWG) between pre-pregnancy and the 1st trimester of 
pregnancy (
Pp–1stGWG). However, the GWG was lower for 1st to 2nd (1st-2ndGWG) and 
3
rd
 trimester of pregnancy to delivery (
3rd–Del
GWG), but it was similar for 2
nd
 to 3
rd
 trimester 
of pregnancy (
2nd-3rdGWG) in both groups of women. Similar findings were seen for the 
rGWG in women from these two groups. The total change in the BMI (BMI) between 
pre-pregnancy and delivery was higher in PGMN compared with PGMO (Table 1). In 
women from the PGMO group, a maximal increase was seen at 
1st-2ndBMI with a lower 
increase in this parameter up to delivery. However, women from the PGMO group showed 
a decrease in the 
Pp–1st
BMI with a negative 
Pp-1stBMI value followed by a continuous 
increase up to delivery. The BMI was lower for 1st-2ndBMI and 3rd-DelBMI, but it was 
similar in 
2nd-3rdBMI in both groups of women. Clinical parameters of newborns from the 
two study groups did not show significant differences. 
 
3.2 L-Arginine transport kinetics and hCAT-1 expression  
The vi for overall 100 µmol/L L-arginine transport was linear up to 60 seconds in 
cells from PGMN and PGMO pregnancies in the absence or presence of tunicamycin, 
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TUDCA, or both molecules (not shown). Values for vi were higher in cells from PGMO 
compared with PGMN (Table 2). Tunicamycin increased the vi in cells from PGMN to 
values close to those in cells from PGMO; however, did not alter this parameter in cells 
from PGMO. TUDCA reversed the increase seen in the vi in cells from PGMO in the 
absence or presence of tunicamycin and in cells from PGMN incubated with tunicamycin. 
However, TUDCA did not alter the vi in cells from PGMN in the absence of this ER stress 
inducer.   
Overall L-arginine transport in the absence or presence of tunicamycin or TUDCA 
was semi-saturable and best-fitted by a non-linear representation in Eadie-Hofstee plots in 
cells from PGMN (Fig. 1A) and PGMO (Fig. 1B). The KD value was lower in PGMO 
compared with PGMN in the absence of tunicamycin or TUDCA (Table 2). None of these 
molecules altered the KD in cells from PGMN; however, tunicamycin increased the KD in 
cells from PGMO pregnancies. TUDCA blocked tunicamycin effect but did not alter the KD 
value in the absence of this ER stress inducer in cells from PGMO.   
After subtracting the linear, non-saturable transport component from overall 
transport, the remaining L-arginine transport was saturable, adjusted to a single Michaelis-
Menten equation, and linear in an Eadie-Hofstee plot (Fig. 1C,D). The saturable transport 
in cells from PGMO showed higher Vmax and maximal transport capacity (Vmax/Km) 
compared with cells from PGMN pregnancies (Table 2). In cells from PGMN, the Vmax and 
Vmax/Km were increased by tunicamycin, an effect blocked by TUDCA. However, TUDCA 
did not alter these parameters in these cells. The increased Vmax and Vmax/Km seen in cells 
from PGMO was unaltered by tunicamycin but blocked by TUDCA in the absence or 
presence of tunicamycin. The apparent Km values were not significantly altered in cells 
from these two study groups in all experimental conditions (Table 2).  
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The hCAT-1 protein abundance was higher in HUVECs from PGMO compared 
with PGMN group (Fig. 1E). Incubation of cells from PGMN with tunicamycin increased 
hCAT-1 protein abundance but unaltered the PGMO-increased abundance of this protein. 
TUDCA reversed the PGMO-increased hCAT-1 protein abundance in the absence of 
presence of tunicamycin but did not alter this protein expression in cells from the PGMN 
group. TUDCA also reversed the increase in the hCAT-1 protein abundance caused by 
tunicamycin in cells from PGMN. 
 
3.3  NOS and arginase activity, and eNOS and Akt protein abundance 
The level of NOS-derived NO detected by fluorescence in DAF-loaded cells was 
lower in cells from PGMO compared with PGMN pregnancies (Fig. 2A). Tunicamycin 
decreased the level of NO in cells from PGMN, an effect blocked by TUDCA. The PGMO-
decreased NO generation was unaltered by tunicamycin but it was partially reversed by 
TUDCA. However, the PGMO-reduced NO level was unaltered by TUDCA in cells 
incubated with tunicamycin. Similar results were found in assays for NOS-activity 
dependent L-citrulline synthesis by h.p.l.c. (Fig. 2B). However, cells from PGMO showed a 
more pronounced reduction in the L-citrulline synthesis in the absence (76  7%) or 
presence (94  5%) of tunicamycin than the NO level detected by the fluorescent assay (38 
 4 and 37  2%, respectively) compared with cells from PGMN. 
Cells from both groups of women show comparable total eNOS protein abundance 
in the absence or presence of tunicamycin or TUDCA (Fig. 2C). The PThr495eNOS 
protein abundance was higher in cells from PGMO compared with PGMN. Tunicamycin 
and TUDCA did not alter the PThr495eNOS protein abundance in cells from PGMN. The 
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effect of PGMO on the PThr495eNOS protein abundance was unaltered by tunicamycin but 
reversed by TUDCA, an effect not seen in cells coincubated with this molecule and 
tunicamycin. In the absence of tunicamycin and TUDCA, the PSer1177eNOS protein 
abundance was lower in cells from PGMO compared with PGMN. Tunicamycin reduced 
the PSer1177eNOS protein abundance in cells from PGMN, an effect that was blocked by 
TUDCA. The PGMO-reduced PSer1177eNOS protein abundance was unaltered by 
tunicamycin but reversed by TUDCA. The effect of this ER stress reducer was absent in 
cells from PGMO coincubated with TUDCA + tunicamycin. 
Total Akt protein abundance was unaltered by PGMO, tunicamycin or TUDCA 
(Fig. 2D). However, the PSer473Akt protein abundance was lower in cells from PGMO 
and reduced by tunicamycin in cells from PGMN. TUDCA blocked the effects of PGMO or 
tunicamycin.  Arginase activity, corresponding to the fraction of urea formation inhibited 
by BEC, was higher in cells from PGMO compared with PGMN pregnancies (Fig. 2E). 
Tunicamycin increased arginase activity in cells from PGMN, an effect blocked by 
TUDCA. The PGMO-increased arginase activity was unaltered by tunicamycin but blocked 
by TUDCA. 
 
3.4.  PERK, eIF2, CHOP, TRB3, and BIP expression 
Total PERK protein abundance was similar in cells from both groups of women in 
the absence or presence of tunicamycin or TUDCA (Fig. 3A). The PThr981PERK protein 
abundance was higher in cells from PGMO compared with PGMN. Tunicamycin increased 
the PThr981PERK protein abundance in cells from PGMN, an effect prevented by 
TUDCA. However, TUDCA did not alter PThr981PERK in these cells. PGMO-increased 
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PThr981PERK protein abundance was unaltered by tunicamycin but blocked by TUDCA 
in the absence or presence of tunicamycin. A similar pattern of responses for total eIF2 
and PSer51eIF2α protein abundance was seen in cells from PGMN or PGMO pregnancies 
(Fig. 3B).  
CHOP and TRB3 protein abundance were higher in cells from PGMO compared 
with PGMN, which was unaltered by tunicamycin but blocked by TUDCA only in the 
absence of the ER stress inducer (Fig. 3C). Tunicamycin increased the CHOP and TRB3 
protein abundance in cells from PGMN, a response blocked by TUDCA in the absence or 
presence of tunicamycin. The relative mRNA level for CHOP, TRB3, and BIP were higher 
in cells from PGMO compared with PGMN (Fig. 3D). PGMO-increased CHOP, TRB3, 
and BIP mRNA levels were unaltered by tunicamycin. TUDCA blocked PGMO effect and 
the increase caused by tunicamycin in the mRNA level for these genes in cells from PGMN 
in the absence of this ER stress inducer. Similar results were obtained when target mRNA 
genes expression was compared against the control gene 28S rRNA (not shown).  
 
3.5  IRE1 and JNK1 expression, and XBP1 mRNA processing 
Total IRE1 protein abundance was higher in cells from PGMO compared with 
PGMN (Fig. 4A). Incubation of cells from PGMN with tunicamycin increased total IRE1 
protein abundance but unaltered the PGMO-increased abundance of this protein. TUDCA 
reversed the PGMO-increased total IRE1 protein abundance in the absence or presence of 
tunicamycin but did not alter the expression of this protein in cells from the PGMN group. 
TUDCA also reversed the increase in the total IRE1 protein abundance caused by 
tunicamycin in cells from PGMN. The PSer724IRE1 protein abundance was unaltered by 
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PGMO or any experimental condition used in this study. The unspliced XBP1 mRNA (164 
bp) level was similar in cells from both groups of women (Fig. 4B). Tunicamycin increased 
the processing of XBP1 mRNA generating a spliced XBP1 mRNA (138 bp), an effect that 
was similar in PGMO and PGMN. 
Total JNK1 protein abundance was unaltered by PGMO, tunicamycin, or TUDCA 
(Fig. 4C). However, PThr183/Tyr185JNK1 protein abundance was higher in cells from 
PGMO, an effect unaltered by tunicamycin but blocked by TUDCA in the absence or 
presence of tunicamycin. In cells from PGMN pregnancies, tunicamycin increased the 
PThr183/Tyr185JNK1 protein abundance which was blocked by TUDCA. 
 
3.6  ATF6 activation 
Confocal immunofluorescence analysis shows that ATF6 protein is expressed in 
cells from PGMN (Fig. 5A) and PGMO groups (Fig. 5B). In the absence of tunicamycin or 
TUDCA, ATF6 was detected mainly at the perinuclear region in cells from PGMN 
pregnancies (Fig. 5C). However, ATF6 was detected in the nuclear region in cells from 
PGMO pregnancies. Tunicamycin increased the ATF6 signal at the nuclear region in cells 
from PGMN but did not alter the nuclear signal for this protein in cells from PGMO. 
TUDCA did not alter the perinuclear distribution of ATF6 signal in cells from PGMN but 
abolished the ATF6 signal at the nuclear region in cells from PGMO pregnancies. TUDCA 
also reduced the tunicamycin-increased signal at the nuclear region resulting in higher 
perinuclear signal for this protein in cells from PGMN pregnancies. In cells from PGMO 
pregnancies treated with tunicamycin, TUDCA reduced the nuclear signal for ATF6 
protein. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
 
4. Discussion 
This study reports that HUVECs from pregnancies with PGMO show increased 
expression and activation of the major ER stress sensors PERK, IRE1, ATF6, and BIP. 
ER stress is a phenomenon that resulted in lower NO synthesis. Thus, PGMO is a 
deleterious condition altering the foetoplacental vasculature at birth due to the generation of 
ER stress. 
Women with PGMO showed lower total variation of GWG (GWG), and reduced 
GWG and rate of GWG (rGWG) during pregnancy except for 2nd–3rd trimesters compared 
with women with PGMN. Total GWG (tGWG) and rGWG for 2
nd–3rd trimesters of 
pregnancy (rGWG
2nd-3rd
) in women with PGMO was within the recommended values for 
pregnant women with pre-pregnancy BMI 30 kg/m2 (tGWG 5–9 kg, rGWG2nd-3rd 0.22 kg 
per week) from the US Institute of Medicine [20]. These findings fit with previous studies 
showing that women that were obese or overweight before pregnancy showed a tGWG and 
rGWG according with the expected values for this group of patients [12,20].    
Interestingly, tGWG, GWG, and rGWG (except for rGWG2nd-3rd) changes in 
women with PGMO were different from PGMN and compared with women that started 
pregnancy with normal weight and BMI but showed supraphysiological rGWG [12]. Thus, 
PGMO may refer to a different metabolic condition compared with women with PGMN 
and supraphysiological rGWG. Indeed, PGMO associates with lower bioenergetics 
performance of human amnion and umbilical cord stem cells [33], higher placental DNA 
methylation [34], or higher placental lesions of maternal vascular supply [35]. These 
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PGMO-associated alterations in the placenta result in adverse intrauterine milieu increasing 
the risk of foetal and newborn disturbances. 
 
4.1 Endothelial L-arginine transport/NO synthesis 
The reduced NO synthesis in HUVECs from PGMO is similar to cells from women 
starting pregnancy with normal weight and BMI but showing supraphysiological rGWG 
[20]. This phenomenon resulted from lower eNOS activity due to higher inhibitor Thr
495
 
phosphorylation of this enzyme [12]. PGMO-reduced NO synthesis also associated with 
reduced eNOS activity, likely due to its lower activator Ser
1177
 in addition to higher 
inhibitor Thr
495
 phosphorylation. However, PGMO-reduced NO synthesis was not due to 
lower eNOS protein abundance. Interestingly, reduced NO synthesis in HUVEC from 
PGMO may result from a lower activation of Akt since its activator phosphorylation at 
Ser
473
 is reduced compared with cells from PGMN. This finding confirms the involvement 
of Akt as a key modulator of NOS (including eNOS) activity in HUVECs [9]. A reduced 
NO bioavailability is also reported in HUVECs from gestational diabetes mellitus 
pregnancies, a phenomenon that could result from increased level of superoxide anion 
which acts as scavenger for NO [9,36-38]. This phenomenon is an alternative mechanism 
by which PGMO may result in reduced NO levels in HUVECs. Thus, PGMO-reduced 
foetoplacental eNOS activity is via a different mechanism than in women with normal pre-
pregnancy weight and BMI but with supraphysiological rGWG. A recent study reported 
higher nitrite/nitrate ratio level, suggestive of higher NO generation, in human placenta 
homogenates from women with PGMO compared with normal pre-pregnancy BMI [37]. 
Unfortunately, NO generation in the placenta was determined in the absence of a NOS 
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inhibitor [37]. In the present study, PGMO associated with lower L-NAME–inhibited (i.e., 
NOS activity) NO level and L-citrulline generation compared with PGMN.  
The amino acid L-arginine is the substrate for NOS to synthesise NO [38]. In 
HUVECs, L-arginine uptake is mediated mainly via the human cationic amino acid 
transporters (hCATs) and system y
+
L activity [22,39–41]. L-Arginine uptake via these 
membrane transporters is required for eNOS activity in HUVECs [40,41]. PGMO 
associated with higher maximal L-arginine transport capacity (Vmax/Km) and expression of 
the hCATs isoform 1 (hCAT-1) in HUVECs. Since L-arginine transport was increased but 
NOS activity was reduced in PGMO the increased transport may result in response to the 
reduced NO synthesis seen in HUVECs. This phenomenon was also suggested for 
HUVECs from women with supraphysiological rGWG [12], preeclampsia [42], and in 
response to ER stress [43]. Also, since intracellular L-arginine is a substrate for arginases in 
HUVECs [29], and arginase activity was higher in these cells from PGMO, it is likely that 
these enzymes will preferentially metabolise this amino acid limiting its availability to 
eNOS in this cell type [44]. Since the apparent Km for L-arginine transport was in the range 
of hCAT-1 described for this cell type (100-200 mol/L) [40,41], the saturable transport 
fitted to a single first order lineal regression in Eadie-Hofstee plots (suggestive of a single 
membrane transport mechanism or more than one mechanism with similar Km) [45], and 
PGMO increased the hCAT-1 protein abundance, increased in hCAT-1 expression and 
activity may explain the higher L-arginine transport in HUVECs from PGMO compared 
with PGMN pregnancies is likely. 
 
4.2 ER stress in PGMO 
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ER stress is induced in HUVECs exposed to the lipid peroxidation product 4-
hydroxy-trans-2-nonenal [46]. Also, activation of the unfolded protein response (UPR) 
initiators PERK, IRE1, and ATF6 is reported in human antecubital vein endothelial cells 
from obese subjects [13]. Interestingly, ER stress associates with endothelial dysfunction 
by reducing eNOS activation [16,18,47] via still unclear mechanisms [9]. Since HUVECs 
from PGMO express high levels of these UPR markers, suggest that PGMO results in ER 
stress in this cell type. PGMO associated with a higher phosphorylation of PERK at Thr
981
 
suggesting PERK activation as reported in HUVECs exposed to lipid peroxidation products 
[46] and endothelial cells from obese subjects [13]. Interestingly, PERK activation 
associated with eNOS uncoupling due to an endoplasmic reticulum redox imbalance-
induced dissociation of HSP90 to eNOS in HUVECs [48]. This phenomenon resulted in 
lower activator Ser
1177
 phosphorylation at eNOS. Thus, PGMO reduced eNOS 
phosphorylation at Ser
1177
 may result from PERK activation in HUVECs. Interestingly, 
PGMO-increased PERK activation was unaltered by the ER stress inducer tunicamycin 
[23], suggesting that obesity effect altering this parameter may be maximal. The latter is 
supported by the findings showing that tunicamycin increased PERK phosphorylation up to 
a comparable level as seen in cells from PGMN. The possibility that PGMO results in ER 
stress in HUVECs is also supported by the results showing that TUDCA, a reducer of ER 
stress [24], blocked the effect of PGMO and tunicamycin on PERK phosphorylation.  
PERK activation results in eIF2α phosphorylation, leading to lower general 
translation but higher translation of several proteins [43]. eIF2α phosphorylation associated 
with an ATF4-mediated increase in CHOP and CAT-1 expression in mammalian cells 
[49,50]. Our findings showed that eIF2α phosphorylation, CHOP mRNA expression, and 
CHOP and hCAT-1 protein abundance were increased in PGMO compared with PGMN. 
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Since eIF2α phosphorylation results in hCAT-1 increased expression in mouse embryonic 
fibroblasts [51,52], PGMO-increased L-arginine transport may result from an inhibitory 
phosphorylation of eIF2α. Also, expression of TRB3, a CHOP-mediated inducible gene in 
ER stress [53], was higher in cells from PGMO. TRB3 is a protein linking ER stress and 
endothelial dysfunction since acts as a pseudokinase blocking Akt activity [54,55], one of 
the main eNOS activators causing its phosphorylation on Ser
1177
 [9,38]. Since PGMO 
associated with lower Akt activator phosphorylation and this effect was reversed by 
TUDCA, PGMO-increased TRB3 level may also involve Akt inactivation. Thus, higher 
TRB3 protein abundance could reduce eNOS activity in HUVECs from PGMO. Changes in 
eIF2α, CHOP, and TRB3 expression were unaltered by tunicamycin but blocked by 
TUDCA in PGMO. Thus, the increase in PERK–eIF2α–CHOP–TRB3 axis suggests that 
PGMO results in increased ER stress in the foetoplacental endothelium. This phenomenon 
ends in lower eNOS activity in HUVECs from PGMO by still unveiled mechanisms. 
Increased CHOP protein abundance and activity downregulates the expression of 
plasma membrane transporters including the human equilibrative nucleoside transporter 1 
(hENT1) in HUVECs [56]. In HUVECs from gestational diabetes mellitus, increased 
CHOP activity reduces h NT1 expression and its Vmax/Km for adenosine transport. Since a 
higher Vmax/Km for L-arginine was found in cells from PGMO as well as in cells from 
PGMN exposed to tunicamycin, a CHOP-mediated increase in the expression of hCAT-1 in 
HUVECs is likely. The possibility that PERK–eIF2α–CHOP–TRB3 axis is responsible for 
the PGMO-increased hCAT-1–mediated L-arginine transport is supported by the fact that 
the increase in PERK (2 fold) and eIF2α (2.6 fold) phosphorylation, and CHOP (2.3 
fold) and TRB3 (1.8 fold) protein abundances were similar to the increase seen in the 
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Vmax/Km for L-arginine (1.6 fold) in cells from this condition. Reports in HUVECs and 
other endothelial cells show that PERK [48], eIF2 [57], CHOP [57] and TRB3 [58] inhibit 
eNOS. Also, changes in the expression and phosphorylation of these ER stress markers 
were similar to the increase in the inhibitor Thr
495
 phosphorylation of eNOS (1.7 fold) and 
reduced NO generation. Thus, PERK–eIF2α–CHOP–TRB3 axis activation lowers eNOS 
activity in HUVECs from PGMO pregnancies. 
IRE-1 is also part of the ER stress response in mammalian cells [50,59]. A redox 
imbalance-induced ER stress in HUVECs causes IRE-1 dissociation from HSP90 leading 
to uncoupled eNOS and lower NO generation [48]. Also, increased IRE-1 expression and 
phosphorylation associated with lower eNOS activity in placental tissues from 
preeclampsia [57]. Since IRE-1 protein abundance, but not its phosphorylation, was 
increased in cells from PGMO (1.8 fold) compared with PGMN, whether IRE-1 
participates in the PGMO-reduced eNOS activity is uncertain. However, since tunicamycin 
did not alter but TUDCA blocked the effect of PGMO on IRE-1 protein abundance, and 
because endothelial cells from obese subjects show increased IRE-1 protein abundance 
[13] and placental tissue extracts from preeclampsia show a parallel increase in IRE-1 
protein abundance and phosphorylation [57], PGMO deleterious consequences for eNOS 
activity may result from increased protein abundance rather than changes in the 
phosphorylation of this ER stress marker. 
IRE-1 causes splicing of XBP-1 in several cell types [50,59]. Redox imbalance-
induced ER stress associated with XBP-1 splicing in HUVECs [46] and increased XBP-1 
expression in placental tissue [57]. However, HUVECs from PGMO show not changes in 
XBP1 mRNA expression and similar splicing in response to tunicamycin than cells from 
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PGMN. Thus, PGMO-induced ER stress may not involve an IRE-1–mediated response in 
HUVECs. Interestingly, increased IRE-1 protein abundance associated with a comparable 
increase in JNK1 phosphorylation in cells from PGMO.  JNK1 is a kinase activated directly 
by the IRE1α kinase domain [60,61]. JNK1 activation results in defective insulin signalling 
due to reduced activation of insulin receptor substrate 1 in HUVECs [9,62]. PGMO 
associates with insulin resistance [63] suggesting that ER stress induced by this maternal 
condition may result in increased IRE-1–JNK1 axis signalling in HUVECs limiting their 
reactivity to insulin. This possibility is supported by the results showing that TUDCA 
inhibits the PGMO-associated increase in JNK1 phosphorylation. Also, cells from PGMN 
pregnancies show higher JNK1 phosphorylation in response to tunicamycin, a response 
blocked by TUDCA, suggesting that ER stress increases JNK1 also in cells from PGMN 
pregnancies. 
A preferential nuclear localization of ATF6 is considered a marker of ER stress 
[13,50,59], as reported in HUVECs [64]. Also, antecubital endothelial cells from obese 
subjects show increased ATF6 nuclear localization compared with non-obese subjects [13]. 
Since HUVECs from PGMO show preferential ATF6 nuclear localization compared with 
cells from PGMN, and this phenomenon was blocked by TUDCA but unaltered by 
tunicamycin, PGMO induced ATF6-associated ER stress in HUVECs. 
In summary, HUVECs from women with PGMO show reduced eNOS activity with 
increased hCAT-1–mediated L-arginine transport as a potential compensatory mechanism 
(Fig. 6). HUVECs from PGMO pregnancies show UPR activation compared with cells 
from PGMN pregnancies. UPR activation results in higher expression of the PERK–eIF2–
CHOP–TRB3 axis signalling, with less clear changes in IRE1–XBP1 axis signalling. UPR 
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activation also resulted in higher nuclear localization of ATF6. Since the changes seen in 
PERK–eIF2–CHOP–TRB3 are similar to the inhibitory phosphorylation of eNOS at 
Thr
495
 and reduced NO levels, and the potential redistribution of ATF6 in the cell, we 
suggest that PGMO is a condition causing ER stress leading to foetoplacental endothelial 
dysfunction. It is worth mentioning that a different maternal metabolic state during 
pregnancy which could be caused by either PGMO or the pregnancy itself may also result 
in altering the parameters described in this study. Also, changes seen in vitro may result as 
an adaptation to culture and not necessarily reflecting a similar situation in vivo. Pre-
pregnancy obesity is a deleterious condition leading to an abnormal newborn phenotype 
that could have serious consequences in its adulthood. Interestingly, TUDCA mitigates ER 
stress-associated endothelial dysfunction in young humans that were subjected to an oral 
glucose load [65], and incubation of HUVECs from normal pregnancies with plasma from 
children with pre-pubertal obesity caused a lower NO synthesis in response to insulin 
involving ER stress [66]. Also, administration of TUDCA increased the response of 
patients with amyotrophic lateral sclerosis to the Amyotrophic Lateral Sclerosis Functional 
Rating Scale Revised test, making likely that ER stress could be a factor involved in the 
subjects with this disease [67]. Even when the latter study did not address whether TUDCA 
effect was due to reducing a potential ER stress in these subjects, it is noticeable to consider 
that these approaches show that using ER stress blockers in humans is safe. Unfortunately, 
nothing has been reported in vivo in human subjects regarding pregnant women with 
PGMO. Considering these findings in vivo we speculate on the possibility that a proper 
management of the ER stress condition in the mother with PGMO may result in a better 
newborn outcome from these pregnancies.  
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Figure 1. Involvement of endoplasmic reticulum stress in L-arginine transport in 
HUVECs. Endothelial cells were isolated from umbilical veins where pregnant 
women were with a normal pre-pregnancy body mass index (PGMN, n = 12 
different women) or with pre-pregnancy obesity (PGMO, n = 12 different women).  
Cells were exposed (8 h) to culture medium without (Control) or with tunicamycin 
(5 mol/L, inducer of endoplasmic reticulum stress), tauroursodeoxycholic acid 
(TUDCA, 100 mol/L, reducer of endoplasmic reticulum stress), or both (see 
Materials and methods). A and B. Overall transport of L-arginine (0–1000 μmol/L 
L-arginine, 1 min, 37°C) was fitted to a single Michaelis-Menten equation increased 
in a linear component and represented in Eadie-Hofstee plots (lower panels).  C and 
D. Saturable transport of L-arginine derived by subtracting the nonsaturable, linear 
component of transport in the range of L-arginine concentrations used in this study 
from the overall transport (see Materials and methods). Data was fitted to a single 
Michaelis-Menten equation and represented in Eadie-Hofstee plots (lower panels). 
E. Western blot (representative of nine experiments) for human cationic amino acid 
transporter 1 (hCAT-1) protein abundance in HUVECs from PGMN (n = 9 different 
women) or PGMO (n = 9 different women). The graph shows hCAT-1/β-actin ratio 
densitometries normalized to 1 in Control in PGMN. In E, *P<0.05 versus Control 
in PGMN, †P<0.05 versus Control and tunicamycin in PGMO, § and ‡ P<0.05 
versus tunicamycin in PGMN and PGMO, respectively. Values are mean ± S.E.M.. 
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Figure 2. Involvement of endoplasmic reticulum stress in eNOS expression and 
activity and arginase activity in HUVECs. Endothelial cells were isolated from 
umbilical veins where pregnant women were with a normal pre-pregnancy body 
mass index (PGMN, n = 9 different women) or with pre-pregnancy obesity (PGMO, 
n = 9 different women). Cells were exposed (8 h) to culture medium without 
(Control) or with tunicamycin (5 mol/L, inducer of endoplasmic reticulum stress), 
tauroursodeoxycholic acid (TUDCA, 100 mol/L, reducer of endoplasmic reticulum 
stress), or both (see Materials and methods). A. Nitric oxide (NO) level detected as 
relative fluorescence units (RFU) measured in cells from PGMN (n = 9 different 
women) and PGMO (n = 9 different women) preloaded with the fluorescent dye 4-
amino-5-methylamino-2′,7′-difluorescein (DAF-FM, 5 μmol/L) in the absence or 
presence of N
G
-nitro-L-arginine methyl ester (L-NAME, 100 μmol/L, NO synthase 
(NOS) inhibitor). Lower panel: Fraction of NO level inhibited by L-NAME (i.e., 
NOS-activity dependent) normalized to 1 in Control in PGMN derived from data in 
the upper panel.  B. L-Citrulline content measured by h.p.l.c. in cells from PGMN 
(n = 3 different women) and PGMO (n = 3 different women) in the absence or 
presence of L-NAME (100 μmol/L) as in A. Lower panel:  Fraction of L-citrulline 
content inhibited by L-NAME (i.e., NOS-activity dependent) derived from data in 
the upper panel. C. Western blot (representative of nine experiments) for total eNOS 
(Total eNOS) (upper panel), eNOS phosphorylated at serine
1177
 (PSer1177-eNOS) 
(middle panel) or threonine
495
 (PThr495-eNOS) (lower panel), and β-actin (internal 
reference) protein abundance in HUVECs from PGMN (n = 9 different women) or 
PGMO (n = 9 different women) as in A. The graphs show Total eNOS/β-actin, 
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PSer1177-eNOS/Total eNOS, or PThr495-eNOS/Total eNOS ratio densitometries 
normalized to 1 in Control in PGMN.  D. Western blot (representative of nine 
experiments) for total Akt (Total Akt), Akt phosphorylated at serine
473
 (PSer473-
Akt), and β-actin (internal reference) protein abundance in HUVECs from PGMN 
(n = 9 different women) or PGMO (n = 9 different women) as in A. The graphs 
show Total Akt/β-actin (upper panel) and PSer1177-Akt/Total Akt (lower panel) 
ratio densitometries normalized to 1 in Control in PGMN.  E. Urea formation 
measured by colorimetry in cells from PGMN (n = 3 different women) and PGMO 
(n = 3 different women) in the absence or presence of S-(2-boronoethyl)-L-cysteine 
(BEC, 20 μmol/L, arginases inhibitor) as in A. Lower panel: Fraction of urea 
formation inhibited by BEC (i.e., arginase-activity dependent) derived from data in 
the upper panel. *P<0.05 versus Control in PGMN, †P<0.05 versus Control and 
tunicamycin in PGMO, § and ‡ P<0.05 versus tunicamycin in PGMN and PGMO, 
respectively. Values are mean ± S.E.M.. 
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Figure 3. Effect of maternal pre-pregnancy obesity on PERK-associated endoplasmic 
reticulum stress markers expression in HUVECs. Endothelial cells were isolated 
from umbilical veins where pregnant women were with a normal pre-pregnancy 
body mass index (PGMN, n = 9 different women) or with pre-pregnancy obesity 
(PGMO, n = 9 different women). Cells were exposed (8 h) to culture medium 
without (Control) or with tunicamycin (5 mol/L, inducer of endoplasmic reticulum 
stress), tauroursodeoxycholic acid (TUDCA, 100 mol/L, reducer of endoplasmic 
reticulum stress), or both (see Materials and methods). A. Western blot 
(representative of nine experiments) for total protein kinase RNA-like endoplasmic 
reticulum kinase (PERK) (Total PERK), PERK phosphorylated at threonine
981
 
(PThr981PERK), and β-actin (internal reference) protein abundance in HUVECs 
from PGMN (n = 9 different women) or PGMO (n = 9 different women). The graph 
shows Total PERK/β-actin ratio densitometries normalized to 1 in Control in 
PGMN. Lower panel: PThr981-PERK/Total PERK ratio densitometries normalized 
to 1 in Control in PGMN.  B. Western blot (representative of nine experiments) for 
total eukaryotic initiation factor 2 (Total eIF2α) and eIF2α phosphorylated at 
serine
51
 (PSer51eIF2α) as in A. The graph shows Total eIF2α/β-actin ratio 
densitometries normalized to 1 in Control in PGMN. Lower panel: PSer51eIF2α 
/total eIF2α ratio densitometries normalized to 1 in Control in PGMN. C. Western 
blot (representative of nine experiments) for total C/EBP homologous protein 10 
(CHOP) and tribbles-like protein 3 (TRB3) as in A. The graphs show Total CHOP 
or TRB3/β-actin ratio densitometries normalized to 1 in Control in PGMN. D. 
Relative mRNA expression for CHOP (upper panel), TRB3 (middle panel), or 
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binding immunoglobulin protein (BIP) (lower panel) in HUVECs as in A. *P<0.05 
versus Control in PGMN, †P<0.05 versus Control and tunicamycin in PGMO, 
§P<0.05 versus tunicamycin in PGMN. Values are mean ± S.E.M.. 
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Figure 4. Effect of maternal pre-pregnancy obesity on IRE1-associated endoplasmic 
reticulum stress markers expression in HUVECs. Endothelial cells were isolated 
from umbilical veins where pregnant women were with a normal pre-pregnancy 
body mass index (PGMN, n = 8 different women) or with pre-pregnancy obesity 
(PGMO, n = 8 different women). Cells were exposed (8 h) to culture medium 
without (Control) or with tunicamycin (5 mol/L, inducer of endoplasmic reticulum 
stress), tauroursodeoxycholic acid (TUDCA, 100 mol/L, reducer of endoplasmic 
reticulum stress), or both (see Materials and methods).  A. Western blot 
(representative of eight experiments) for total inositol-requiring enzyme 1α (Total 
IRE1α), IRE1α phosphorylated at serine724 (P-Ser724IRE1α), and β-actin (internal 
reference) protein abundance in HUVECs from PGMN (n = 8 different women) or 
PGMO (n = 8 different women). The graph shows Total IRE1α/β-actin ratio 
densitometries normalized to 1 in Control in PGMN. Lower panel: 
P~Ser
724IRE1α/Total IRE1α ratio densitometries normalized to 1 in Control in 
PGMN. B. Level of the unspliced (XBP1us, 164 pb) or spliced (XBP1s, 138 bp) 
mRNA for X-box binding protein 1 (XBP1) and 28S rRNA (housekeeper) 
(representative of eight experiments) for cells incubated without (Control) or with 
tunicamycin as in A. The graph shows XBP1 mRNA/28S rRNA ratio 
densitometries normalized to 1 in cells from PGMN in the absence of tunicamycin. 
C. Western blot (representative of eight experiments) for total c-Jun N-terminal 
kinase 1 (Total JNK1), JNK1 phosphorylated at threonine
183
 and tyrosine
185
 
(PThr183/Tyr185JNK1), and β-actin as in A. The graph shows Total JNK1/β-actin 
ratio densitometries normalized to 1 in Control in PGMN. Lower panel: 
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PThr183/Tyr185JNK1/Total JNK1 ratio densitometries normalized to 1 in Control in 
PGMN. *P<0.05 versus Control in PGMN, †P<0.05 versus Control and 
tunicamycin in PGMO, § and ‡ P<0.05 versus tunicamycin in PGMN and PGMO, 
respectively, 
¶
P<0.05 versus Control in PGMO. Values are mean ± S.E.M.. 
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Figure 5. Effect of maternal pre-pregnancy obesity on ATF6-associated endoplasmic 
reticulum stress marker location in HUVECs. Endothelial cells were isolated 
from umbilical veins where pregnant women were with a normal pre-pregnancy 
body mass index (PGMN, n = 8 different women) or with pre-pregnancy obesity 
(PGMO, n = 8 different women). Cells were exposed (8 h) to culture medium 
without (Control) or with tunicamycin (5 mol/L, inducer of endoplasmic reticulum 
stress), tauroursodeoxycholic acid (TUDCA, 100 mol/L, reducer of endoplasmic 
reticulum stress), or both (see Materials and methods). Confocal microscopy 
immunofluorescence of activating transcription factor 6 (ATF6) (red fluorescence) 
and nuclei (blue fluorescence, counterstained with DAPI) was assayed. Fifteen 
confocal images were taken through the Z-axis (each 0.3 μm) from the bottom to the 
top of the cells (see Materials and methods).  A. Pictures represent Z-stacked images 
(15 images).  B. Pictures show the Z-plane for the optical slide number 7, i.e., 2.1-
2.4 m from cell culture surface. An amplification is shown at the inserts in each 
picture. Bars are for all corresponding pictures at 60X microscopy magnifications.  
Negative control for ATF6 (i.e., without antibody against ATF6) and DAPI in cells 
from PGMN.  C. Immunofluorescent signal at the nuclear over the perinuclear 
region (see Materials and methods). *P<0.05 versus Control in PGMN, †P<0.05 
versus Control and tunicamycin in PGMO, § and ‡ P<0.05 versus tunicamycin in 
PGMN and PGMO, respectively. Values are mean ± S.E.M.. 
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Figure 6. The potential involvement of pre-pregnancy maternal obesity-induced 
endoplasmic reticulum stress in human umbilical vein endothelial cell 
dysfunction. Pre-pregnancy maternal obesity (PGMO) associates with an increase 
() in the expression and activity of markers of endoplasmic reticulum stress in 
human umbilical vein endothelial cells. Among these markers, activation of the 
protein kinase RNA-like endoplasmic reticulum kinase (PERK) and its downstream 
targets the eukaryotic initiation factor 2 (eIF2α), C/EBP homologous protein 10 
(CHOP), and tribbles-like protein 3 (TRB3) is seen in cells from PGMO. This 
maternal condition also increased total protein abundance but not the 
phosphorylation at serine
724
 of the inositol-requiring enzyme 1α (IRE1α). PGMO 
associated with higher phosphorylation of c-Jun N-terminal kinase 1 (JNK1), a 
downstream target of IRE1α. The location of the activating transcription factor 6 
(ATF6) was preferentially in a nuclear region in cells from PGMO. The reducer of 
endoplasmic reticulum stress tauroursodeoxycholic acid blocked PGMO effects in 
PERK signalling and ATF6 preferential location in the nuclear region. PERK–
eIF2α–CHOP–TRB3 signalling decreased () the activity of endothelial nitric 
oxide synthase (eNOS) leading to a lower level of NO paralleled by an increase in 
the L-arginine transport via the human cationic amino acid transporter 1 (hCAT-1) 
expression and maximal transport capacity for L-arginine in HUVECs from PGMO. 
The modulation of L-arginine transport and NO synthesis is mediated by still 
unknown (?) mechanisms. Green arrows refer to activation and large orange arrows 
represent a biological effect of PERK and IRE1α signalling.  
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Table 1. Clinical characteristics of pregnant women and the newborns 
Variables     PGMN 
    (n = 20) 
   PGMO 
   (n = 22) 
 
Maternal variables 
  
 Age (years) 29.3 ± 4.3 (24–37) 30.6 ± 5.7 (21–45) 
 Height (cm) 161 ± 5 (152–170) 158 ± 5 (148–171) 
 Weight (kg)   
  Pre-pregnancy 
a
 56.0 ± 6.5 (45–65) 83.5 ± 16.6 * (70.2–127) 
  1
st
 trimester
 
57.1 ± 6.0 (45.5–65.5) 83.3 ± 18.3 * (65–127) 
  2
nd
 trimester
 
64.1 ± 3.1 (59.6–70) 87.5 ± 18.6 * (67.5–130) 
  3
rd
 trimester 66.9 ± 6.4 (51–74) 90.0 ± 18.1 * (70–132) 
  Delivery 70.6 ± 5.1 (56.8–83) 90.2 ± 14.8 * (72–135) 
 GWG (kg)   
  Total 
b
 14.6 ± 3.9 (11.8–18.0) 6.7 ± 4.0 * (5.0–9.0) 
  Pre-pregnancy to 1
st
 trimester 1.1 ± 1.3 (0.5–2.5) -0.2 ± 0.5 * (-0.9–1) 
  1
st
 to 2
nd
 trimester 7.0 ± 1.1 (5.0–8.2) 4.2 ± 1.4 * (1.5–5.0) 
  2
nd
 to 3
rd
 trimester 2.8 ± 2.6 (2.0–5.0) 2.5 ± 2.7 (1.5–6.0) 
  3
rd
 trimester to delivery 3.7 ± 2.1 (2.0–6.2) 0.2 ± 2.3 * (0.0–1.5) 
 rGWG (kg/week)
 c
   
  Pre-pregnancy to 1
st
 trimester 0.09 ± 0.10 (0.04–0.21) -0.02 ± 0.03 * (-0.08–0.08) 
  1
st
 to 2
nd
 trimester 0.58 ± 0.08 (0.42–0.68) 0.35 ± 0.10 * (0.10–0.42) 
  2
nd
 to 3
rd
 trimester 0.23 ± 0.21 (0.17–0.42) 0.21 ± 0.22 (0.13–0.20) 
  3
rd
 trimester to delivery 0.31 ± 0.18 (0.17–0.52) 0.02 ± 0.20 * (0.05–0.13) 
 BMI (kg/m
2
)   
  Pre-pregnancy 
d
 22.1 ± 2.1 (18.7–24.4) 32.8 ± 5.1 * (30.0–50.9) 
  1
st
 trimester
 
2
nd
 trimester 
3
rd
 trimester 
22.5 ± 1.2 (21.1–24.6) 
24.6 ± 1.6 (22.9–27.9) 
26.1 ± 2.0 (21.8–28.4) 
32.1 ± 4.1 * (30.0–52.0) 
32.5 ± 4.1 * (30.1–42.8) 
33.7 ± 3.8 * (31.2–45.4) 
  Delivery 27.4 ± 1.3 (24.3–28.9) 35.9 ± 5.0 * (32.0–54.1) 
 BMI (kg/m2)   
  Total 
e
 5.3 ± 0.4 (2.0–7.7) 3.1 ± 0.5 * (2.1–7.4) 
  Pre-pregnancy to 1
st
 trimester 0.4 ± 0.1 (0.1–1.0) -0.7 ± 0.1* (-1.2–0.5) 
  1
st
 to 2
nd
 trimester 2.1 ± 0.1 (1.2–3.1) 0.4 ± 0.1 * (0.2–0.8) 
  2
nd
 to 3
rd
 trimester 1.5 ± 0.1 (0.8–2.9) 1.2 ± 0.1 (0.7–1.8) 
  3
rd
 trimester to delivery 1.3 ± 0.1 (0.6–2.5) 2.2 ± 0.3 * (1.6–2.9) 
 Blood pressure at 1
st
 trimester (mmHg)   
  Systolic 
Diastolic 
Mean 
104 ± 11 (90–122) 
63 ± 10 (50–78) 
84 ± 10 (70–98) 
111 ± 12 (90–129) 
70 ± 8 (60–80) 
90 ± 10 (75–105) 
 Blood pressure at 2
nd
 trimester (mmHg)   
  Systolic 
Diastolic 
Mean 
102 ± 10 (85–115) 
63 ± 8 (50–70) 
82 ± 8 (70–90) 
111 ± 8 (100–120) 
66 ± 5 (60–70) 
88 ± 6 (80–95) 
 Blood pressure at 3
rd
 trimester (mmHg)   
  Systolic 108 ± 11 (90–125) 113 ± 9 (100–120) 
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Pregnant women were with a normal pre-pregnancy with a normal pre-pregnancy body 
mass index (BMI 18.5–24.9 kg/m2) (PGMN) or with pre-pregnancy obesity (BMI 30 
kg/m
2
) (PGMO) according to the US Institute of Medicine guidelines (IOM, 2009). 
a
 Pre-
pregnancy weight corresponds to self-reported weight by the pregnant women at their first 
interview with the medical specialist (i.e., 9–19 weeks of pregnancy) or the annotated 
weight in clinical charts after routine medical screening (i.e., 2–3 months before 
pregnancy). Maternal weight was measured at the 1
st
 (0–14 weeks of gestation), 2nd (14–28 
weeks of gestation), 3
rd
 (28–40 weeks of gestation) trimesters of pregnancy and at delivery 
(37.1–41 weeks of gestation). b The total change in gestational weight gain (GWG Total) 
corresponds to the difference between the weight at pre-pregnancy and delivery. 
c
 Rates of 
GWG (rGWG) corresponds to GWG (kg)/12 (weeks). d Pre-pregnancy BMI was 
calculated using the pre-pregnancy weight. 
e
 The total change in BMI (BMI Total) 
corresponds to the difference between the BMI at pre-pregnancy and delivery. Oral glucose 
tolerance test (OGTT) (75 g glucose) was measured between 24–28 weeks of gestation. 
Values are mean ± S.D. (range). *P<0.05 versus corresponding values in PGMN.  
Diastolic 
Mean 
70 ± 8 (60–85) 
89 ± 8 (75–105) 
72 ± 7 (60–80) 
92 ± 7 (80–100) 
 Basal glycaemia at delivery (mg/dL) 
OGTT (mg/dL) 
79 ± 4 (73–85)  78 ± 6 (69–94) 
  Glycaemia basal 76 ± 5 (68–85) 77 ± 9 (67–95) 
  Glycaemia 2 h after glucose load 93 ± 19 (56–125) 99 ± 20 (60–135) 
   
Newborn variables   
 Sex (female/male) 11/9 10/12 
 Gestational age (weeks) 39.3 ± 1.1 (37.1–41) 39.3 ± 1.0 (37.7–40.9) 
 Birth weight (grams) 3263 ± 274 (2810–3750) 3345 ± 304 (2770–3980) 
 Height (cm) 50.2 ± 1.5 (48–54) 50.1 ± 1.4 (48–53) 
 Ponderal index (grams/cm
3
 x 100) 2.6 ± 0.2 (2.2–3) 2.7 ± 0.3 (2.3–3.1) 
 Umbilical vein glycaemia (mg/dL) 64.8 ± 1.8 (48.6–73-9) 68.5 ± 1.8 (57.7–77.5) 
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Table 2. Kinetic parameters for L-arginine transport in HUVECs from PGMN and PGMO 
pregnancies 
 
Saturable transport 
 
Overall transport 
Vmax 
(pmol/µg 
protein/ 
min) 
 Km 
(µmol/L) 
 Vmax/Km 
(pmol/µg 
protein/ 
min/(µmol/L)) 
 KD  
(pmol/µg 
protein/ 
min/(µmol/L)) 
 vi  
(pmol/µg 
protein/ 
0.5 s) 
 
PGMN 
          
          
 Control  3.86 ± 
0.29 
 195 ± 42  0.0198 ± 
0.0029 
 0.0081 ± 
0.0042 
  0.0069 
± 0.0001 
 
 Tunicamycin  9.50 ± 
0.30 * 
 220 ± 45  0.0432 ± 
0.0094 * 
 0.0109 ± 
0.0025 
  0.0150 
± 0.0001* 
 
 TUDCA  4.85 ± 
0.35 
 224 ± 35  0.0217 ± 
0.0025 
 0.0099 ± 
0.0013 
  0.0075 
± 0.0002 
 
 Tunicamycin 
+ TUDCA 
 4.06 ± 
0.43 
 152 ± 51  0.0267 ± 
0.0058 
 0.0114 ± 
0.0018 
  0.0088 
± 0.0001 
 
             
PGMO 
          
          
 Control  7.26 ± 
0.59 * 
 253 ± 58  0.0287 ± 
0.0043 * 
 0.0021 ± 
0.0010 * 
  0.0099 
± 0.0001 
* 
 
 Tunicamycin  7.67 ± 
0.49 * 
 193 ± 36  0.0397 ± 
0.0049 * 
 0.0102 ± 
0.0031 † 
  0.0102 
± 0.0002 * 
 
 TUDCA  4.71 ± 
0.63 † 
 203 ± 77  0.0023 ± 
0.0005 † 
 0.0084 ± 
0.0026 † 
  0.0070 
± 0.0002 
† 
 
 Tunicamycin 
+ TUDCA 
 4.06 ± 
0.10 † 
 271 ± 18  0.0015 ± 
0.0001 † 
 0.0064 ± 
0.0005 † 
  0.0052 
± 0.0002 
† 
 
             
 
Legend for Table 2 in the next page. 
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Legend for Table 2 
 
L-Arginine transport was measured in HUVECs from women with a normal pre-pregnancy 
body mass index (BMI 18.5–24.9 kg/m2) (PGMN, n = 12 different women) or from women 
with pre-pregnancy obesity (BMI 30 kg/m2) (PGMO, n = 12 different women). Cells were 
coincubated (8 h) in the absence (Control) or presence of tunicamycin (5 mol/L, an 
inducer of endoplasmic reticulum stress) and/or tauroursodeoxycholic acid (TUDCA, 100 
mol/L, a reducer of endoplasmic reticulum stress) (see Materials and methods). Saturable 
transport of L-arginine was derived by subtracting the non-saturable, linear component of 
transport in the range of L-arginine concentrations used in this study from the overall 
transport (see Materials and methods). Maximal velocity (Vmax) and apparent Michaelis-
Menten constant (Km) of saturable transport were calculated assuming a single Michaelis-
Menten hyperbola. Vmax/Km represents maximal L-arginine transport capacity. The linear 
phase of overall transport of L-arginine (KD) was obtained from transport data fitted to a 
Michaelis-Menten equation increased in a linear component. Initial velocity (vi) was 
calculated for 0.5 s with 100 µmol/L L-arginine transport. *P<0.05 versus all other 
corresponding values in PGMN. †P<0.05 versus corresponding Control or Tunicamycin 
values. Values are mean ± S.E.M.. 
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58 
Highlights 
 
 Pre-pregnancy maternal obesity (PGMO) induces ER stress in HUVECs 
 PGMO increases PERK and IRE1 activity, and ATF6 nuclear localization in 
HUVECs 
 PERK targets eIF2, CHOP, and TRB3 are activated/overexpressed in HUVECs 
from PGMO 
 TUDCA blocked the PGMO-lower NO synthesis and higher L-arginine transport in 
HUVECs 
 PGMO-induced ER stress results in foetoplacental endothelial dysfunction at birth 
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